Vitrectomy in proliferative diabetic retinopathy, the last 10 years

Article

Highlighting the evolving trends in surgical technique and the impact on disease management

This report aims to highlight the evolving trends in surgical management of this complex vitreoretinal disorder and provides some insight into current practice and evidence-based medicine. We will also report our own experiences and share 10 year anatomical and visual outcome in patients who underwent 20-gauge (20G) pars plana vitrectomy (PPV) for complications of PDR under the supervision of a single surgeon (THW) at a teaching hospital in south east London, UK.

Vitrectomy surgery

Smaller gauge transconjunctival sutureless vitrectomy offers theoretical advantages of shorter surgical time, less postoperative inflammation, faster visual recovery and improved patient comfort. But these benefits are balanced in complex vitreoretinal adhesion and fibrovascular proliferations - seen in PDR as a result of altered fluidics with reduced flow through the smaller probe as compared to 20G. Advances such as 25G ultra high speed PPV machinery9 that has better fluid dynamic control, high speed cutting rate (5000 cuts per minute) and viscodissection assisted microincision vitrectomy10 offer new options in microincision vitrectomy.

Anatomical and visual results following PPV in complications due to DR with different gauges of vitrectomy instrumentation are comparable. In a retrospective study of 101 eyes by Park et al.11 no beneficial effects on anatomical and visual outcome were seen after direct comparison between 20- and 23-G PPV. However, there were more cases of hypotony in the 23-G PPV group.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
Related Content
© 2025 MJH Life Sciences

All rights reserved.